B
TNGX icon

Braslyn’s Tango Therapeutics TNGX Stock Holding History

Braslyn’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,961
Closed -$208K – 2
2024
Q3 		$208K Hold
26,961
– – 1.64% 2
2024
Q2 		$231K Hold
26,961
– – 2.77% 2
2024
Q1 		$214K Hold
26,961
– – 9.12% 2
2023
Q4 		$267K Buy
+26,961
New +$234K 0.14% 3

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Braslyn's TNGX Position: Q4 2024 in Review

Braslyn sold out of Tango Therapeutics (TNGX) in Q4 2024, closing a stake of 26,961 shares — an estimated $208K sold.

Braslyn first reported a position in TNGX in Q4 2023 and held it in 4 quarters. The position peaked at $267K in Q4 2023. 137 funds tracked by Wall St. Rank hold TNGX as of Q4 2024.

  • Braslyn reported no remaining Tango Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Braslyn sold 26,961 Tango Therapeutics shares in Q4 2024, an estimated $208K.
  • Braslyn first reported a position in Tango Therapeutics in Q4 2023 and held it in 4 quarters.
  • Braslyn's Tango Therapeutics position peaked at $267K in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2024.

Based on Braslyn's 13F filing for Q4 2024, filed 14 Feb 2025.